These outcomes should shed some light towards a better understanding of the utility of GLP-1 agonists in diabetes- or hyperglycemia-induced cardiac anomalies, which merit further investigation in a more clinically relevant setting. This evidence concerns the gene GCG and Hyperglycemia.